Cure8 trial brief
This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission rates in patients aged 65+.
Older adults with ulcerative colitis, caregivers, gastroenterologists, researchers studying S1P modulators or geriatric IBD
This ClinicalTrials.gov record describes a single-center interventional study enrolling elderly (age ≥65) patients with active ulcerative colitis to receive oral etrasimod 2 mg daily and to have clinical course, adverse events, endoscopic findings, and biopsy histology collected prospectively.
The trial’s primary outcome is clinical remission at 4 weeks measured by a Clinical Activity Index score <4. Planned enrollment is 30 participants at Showa Inan General Hospital (Nagano, Japan).
Eligibility excludes patients with significant comorbidities such as renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, or active infection. The record is a trial registration (recruiting) and reports planned design and endpoints rather than results.
This entry focuses on older adults specifically; it does not provide efficacy or safety outcomes yet.
Registered on ClinicalTrials.gov as a recruiting interventional study. The record lists planned procedures (endoscopy with biopsy) and a short 4-week primary endpoint; no outcomes or results are reported in this entry.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
